These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34743191)

  • 1. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
    Gadi D; Griffith A; Tyekucheva S; Wang Z; Rai V; Vartanov A; Thrash E; Fernandes SM; Lehmberg TZ; Lee B; Martindale SP; Machado JH; Odejide O; Armand P; Fisher DC; Arnason J; Davids MS; Lederer JA; Brown JR
    Leukemia; 2022 Mar; 36(3):723-732. PubMed ID: 34743191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
    Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
    Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
    Izutsu K; Kinoshita T; Takizawa J; Fukuhara S; Yamamoto G; Ohashi Y; Suzumiya J; Tobinai K
    Jpn J Clin Oncol; 2021 Mar; 51(3):408-415. PubMed ID: 33244584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
    Davids MS; Fisher DC; Tyekucheva S; McDonough M; Hanna J; Lee B; Francoeur K; Montegaard J; Odejide O; Armand P; Arnason J; Brown JR
    Leukemia; 2021 Apr; 35(4):1064-1072. PubMed ID: 32820271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
    Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
    Vangapandu HV; Jain N; Gandhi V
    Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.
    Gauthier M; Durrieu F; Martin E; Peres M; Vergez F; Filleron T; Obéric L; Bijou F; Quillet Mary A; Ysebaert L
    BMC Cancer; 2019 Aug; 19(1):809. PubMed ID: 31412798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A; Raikar SS; Koff JL; Flowers CR; Coma S; Pachter JA; Ravindranathan S; Spencer HT; Shanmugam M; Waller EK
    Blood; 2022 Jan; 139(4):523-537. PubMed ID: 35084470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
    Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
    Hanlon A; Brander DM
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duvelisib for the treatment of chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
    Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
    Patel VM; Balakrishnan K; Douglas M; Tibbitts T; Xu EY; Kutok JL; Ayers M; Sarkar A; Guerrieri R; Wierda WG; O'Brien S; Jain N; Stern HM; Gandhi V
    Leukemia; 2017 Sep; 31(9):1872-1881. PubMed ID: 28017967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
    Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report.
    Lolli G; Casadei B; Pellegrini C; Argnani L; Cocito F; Zinzani PL
    Tumori; 2021 Dec; 107(6):NP105-NP107. PubMed ID: 34167407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
    Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
    J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
    Nikolaenko L; Liu T; Danilov AV
    Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
    [No Abstract]   [Full Text] [Related]  

  • 18. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
    Gassner FJ; Weiss L; Geisberger R; Hofbauer JP; Egle A; Hartmann TN; Greil R; Tinhofer I
    Cancer Immunol Immunother; 2011 Jan; 60(1):75-85. PubMed ID: 20857100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
    Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.